Ritter Pharmaceuticals, Inc. Issued Method Of Use Patent For RP-G28

LOS ANGELES, CA--(Marketwired - June 28, 2016) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that it recently has been issued U.S. Patent No. 9,370,532 by the U.S. Patent & Trademark Office.

U.S. Patent No. 9,370,532 covers methods for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Subject to the payment of maintenance fees, this patent will remain in force until 2030.

"We are excited to have received additional patent protection related to RP-G28, our treatment for lactose intolerance which has the potential to be the first FDA-approved treatment for this indication," commented Michael D. Step, Chief Executive Officer of Ritter Pharmaceuticals. "As announced earlier this year, we gained patent protection for the manufacturing and composition of RP-G28. This new patent will provide us with further protection as we work to bring a safe and effective treatment to patients suffering from lactose intolerance and to achieve long-term value for the company and its shareholders."

About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company is advancing human gut health research by exploring the metabolic capacity of gut microbiota, and translating the functionality of these microbiome modulators into safe and effective applications. Their lead drug candidate, RP-G28, has the potential to become the first FDA-approved drug for lactose intolerance, a condition that affects more than one billion people worldwide.

Forward-Looking Statements
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company is advancing human gut health research by exploring the metabolic capacity of gut microbiota, and translating the functionality of these microbiome modulators into safe and effective applications. Their lead drug candidate, RP-G28, has the potential to become the first FDA-approved drug for lactose intolerance, a condition that affects more than one billion people worldwide.